HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert J. Keenan Akihiko Kawai Robert L. Hardesty Bartley P. Griffith Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keenan, R. J. Articles by Griffith, B. P. Search for Related Content PubMed PubMed Citation Articles by Keenan, R. J. Articles by Griffith, B. P. Related Collections Related Articles

Ann Thorac Surg 1995;60:580-584
© 1995 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Clinical Trial of Tacrolimus Versus Cyclosporine in Lung Transplantation

Divisions of Cardiothoracic Surgery and Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Background. A prospective clinical trial was undertaken to compare the efficacy of tacrolimus (FK 506) versus cyclosporine as the primary immunosuppressive agent after lung transplantation.

Methods. Between October 1991 and May 1994, 133 single-lung and bilateral-lung recipients were randomized to receive either cyclosporine (n = 67) or tacrolimus (n = 66). The two groups were similar in age, sex, and underlying disease.

Results. One-year and 2-year survival rates were similar in the two groups, although the trend was toward increased survival with tacrolimus. Acute rejection episodes per 100 patient-days were fewer (p = 0.07) in the tacrolimus group (0.85) than in the cyclosporine group (1.09). Obliterative bronchiolitis developed in significantly fewer patients in the tacrolimus group (21.7%) compared with the cyclosporine group (38%) (p= 0.025), and there was greater freedom from obliterative bronchiolitis over time for patients receiving tacrolimus (p < 0.03). Significantly more cyclosporine-treated patients (n = 13) required crossover to tacrolimus than tacrolimus-treated patients to cyclosporine (n = 2) (p = 0.02). The switch to tacrolimus controlled persistent acute rejection in 6 of 9 patients. The overall incidence of infections was similar in the two groups, although bacterial infections were more common with cyclosporine (p = 0.0375), whereas the risk of fungal infection was higher with tacrolimus (p < 0.05).

Conclusions. This trial demonstrates the advantage of tacrolimus in reducing the risk of obliterative bronchiolitis, the most important cause of long-term morbidity and mortality after lung transplantation.

Related Articles

Advantage-FK 506: Reduced Chronic Rejection for Lung Transplant Recipients

R. Morton Bolman, III
Ann. Thorac. Surg. 1995 60: 495-496. [Extract] [Full Text]

This article has been cited by other articles:

				S. Korom, A. Boehler, and W. Weder Immunosuppressive therapy in lung transplantation: state of the art Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 1045 - 1055. [Abstract] [Full Text] [PDF]

				S. M. Bhorade and E. Stern Immunosuppression for Lung Transplantation Proceedings of the ATS, January 15, 2009; 6(1): 47 - 53. [Abstract] [Full Text] [PDF]

				J. A. Belperio, S. S. Weigt, M. C. Fishbein, and J. P. Lynch III Chronic Lung Allograft Rejection: Mechanisms and Therapy Proceedings of the ATS, January 15, 2009; 6(1): 108 - 121. [Abstract] [Full Text] [PDF]

				A. Y. Sheikh, M. P. Pelletier, and R. C. Robbins Heart-Lung and Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1579 - 1608. [Full Text]

				N. Ide, T. Nagayasu, K. Matsumoto, T. Tagawa, K. Tanaka, T. Taguchi, Y. Sumida, and M. Nakashima Efficacy and safety of inhaled tacrolimus in rat lung transplantation J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 548 - 553. [Abstract] [Full Text] [PDF]

				I. Al-Githmi, N. Batawil, N. Shigemura, M. Hsin, T. W. lee, G.-W. He, and A. Yim Bronchiolitis obliterans following lung transplantation Eur. J. Cardiothorac. Surg., December 1, 2006; 30(6): 846 - 851. [Abstract] [Full Text] [PDF]

				J. L. Taylor and S. M. Palmer Critical Care Perspective on Immunotherapy in Lung Transplantation J Intensive Care Med, December 1, 2006; 21(6): 327 - 344. [Abstract] [PDF]

				L. P. Nicod Mechanisms of airway obliteration after lung transplantation. Proceedings of the ATS, July 1, 2006; 3(5): 444 - 449. [Abstract] [Full Text] [PDF]

				G. Warnecke, M. Avsar, T. Steinkamp, R. Reinhard, J. Niedermeyer, A. R. Simon, A. Haverich, and M. Struber Tacrolimus versus cyclosporine induction therapy in pulmonary transplantation in miniature swine Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 454 - 460. [Abstract] [Full Text] [PDF]

				K. Sarahrudi, M. Estenne, P. Corris, J. Niedermayer, C. Knoop, A. Glanville, C. Chaparro, G. Verleden, M. W. Gerbase, F. Venuta, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1126 - 1132. [Abstract] [Full Text] [PDF]

				C. Knoop, A. Haverich, and S. Fischer Immunosuppressive therapy after human lung transplantation Eur. Respir. J., January 1, 2004; 23(1): 159 - 171. [Abstract] [Full Text] [PDF]

				K J Ahn, J W Lee, S T Hahn, D W Yang, P S Kim, H J Kim, and C C Kim Diffusion-weighted MRI and ADC mapping in FK506 neurotoxicity Br. J. Radiol., December 1, 2003; 76(912): 916 - 919. [Abstract] [Full Text] [PDF]

				A. DeVito Dabbs, L. A. Hoffman, A. T. Iacono, C. L. Wells, W. Grgurich, T. G. Zullo, K. R. McCurry, and J. H. Dauber Pattern and Predictors of Early Rejection After Lung Transplantation Am. J. Crit. Care., November 1, 2003; 12(6): 497 - 507. [Abstract] [Full Text] [PDF]

				A. Zuckermann, H. Reichenspurner, T. Birsan, H. Treede, E. Deviatko, B. Reichart, and W. Klepetko Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: One-year results of a 2-center prospective randomized trial J. Thorac. Cardiovasc. Surg., April 1, 2003; 125(4): 891 - 900. [Abstract] [Full Text] [PDF]

				L. B. Balsam, D. D. Yuh, R. C. Robbins, and B. A. Reitz Heart-Lung and Lung Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1461 - 1490. [Full Text]

				R. E. Dupuis, D. J. Taber, A. L. Fann, and K. P. Lumbert Medical Management Considerations for Patients With Lung Transplantation Journal of Pharmacy Practice, August 1, 2001; 14(4): 258 - 276. [Abstract] [PDF]

				J. W. K. van den Berg, P. J. van Enckevort, E. M. TenVergert, D. S. Postma, W. van der Bij, and G. H. Koeter Bronchiolitis Obliterans Syndrome and Additional Costs of Lung Transplantation Chest, December 1, 2000; 118(6): 1648 - 1652. [Abstract] [Full Text] [PDF]

				J W K van den Berg, D S Postma, G H Koëter, and W van der Bij New immunosuppressive drugs and lung transplantation: last or least? Thorax, June 1, 1999; 54(6): 550 - 553. [Full Text]

				S. M. Arcasoy and R. M. Kotloff Lung Transplantation N. Engl. J. Med., April 8, 1999; 340(14): 1081 - 1091. [Full Text] [PDF]

				D. Metras, L. Viard, B. Kreitmann, A. Riberi, A. Pannetier-Mille, O. Garbi, J.-Y. Marti, and P. Geigle Lung infections in pediatric lung transplantation: experience in 49 cases Eur. J. Cardiothorac. Surg., April 1, 1999; 15(4): 490 - 495. [Abstract] [Full Text] [PDF]

				J. Longoria, R. F. Roberts, C. C. Marboe, B. C. Stouch, V. A. Starnes, and M. L. Barr SIROLIMUS (RAPAMYCIN) POTENTIATES CYCLOSPORINE IN PREVENTION OF ACUTE LUNG REJECTION J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 714 - 718. [Abstract] [Full Text] [PDF]

				J. C. Wain, C. D. Wright, D. P. Ryan, S. L. Zorb, D. J. Mathisen, and L. C. Ginns Induction immunosuppression for lung transplantation with OKT3 Ann. Thorac. Surg., January 1, 1999; 67(1): 187 - 193. [Abstract] [Full Text] [PDF]

				G. K. Thyagarajan, A. Cobanoglu, and W. Johnston FK506-Induced Fulminant Leukoencephalopathy After Single-Lung Transplantation Ann. Thorac. Surg., November 1, 1997; 64(5): 1461 - 1464. [Abstract] [Full Text]

				R. I. Whyte, S. J. Rossi, M. S. Mulligan, R. Florn, L. Baker, S. Gupta, F. J. Martinez, and J. P. Lynch III Mycophenolate Mofetil for Obliterative Bronchiolitis Syndrome After Lung Transplantation Ann. Thorac. Surg., October 1, 1997; 64(4): 945 - 948. [Abstract] [Full Text]

				R. J. Keenan, A. Iacono, J. H. Dauber, A. Zeevi, S. A. Yousem, N. P. Ohori, G. J. Burckart, A. Kawai, G. C. Smaldone, and B. P. Griffith TREATMENT OF REFRACTORY ACUTE ALLOGRAFT REJECTION WITH AEROSOLIZED CYCLOSPORINE IN LUNG TRANSPLANT RECIPIENTS J. Thorac. Cardiovasc. Surg., February 1, 1997; 113(2): 335 - 341. [Abstract] [Full Text]

				P. Mattsson, A. Zeevi, J. Cai, S. A. Yousem, R. Hoffman, M. Nalesnik, G. J. Burckart, D. Geller, and B. P. Griffith Effect of Aminoguanidine and Cyclosporine on Lung Allograft Rejection Ann. Thorac. Surg., July 1, 1996; 62(1): 207 - 212. [Abstract] [Full Text]

				R. M. Bolman III Advantage-FK 506: Reduced Chronic Rejection for Lung Transplant Recipients Ann. Thorac. Surg., September 1, 1995; 60(3): 495 - 496. [Full Text]